FY2022 EPS Estimates for Vanda Pharmaceuticals Inc. Lifted by Analyst (NASDAQ:VNDA)
FY2022 EPS Estimates for Vanda Pharmaceuticals Inc. Lifted by Analyst (NASDAQ:VNDA)
Vanda Pharmaceuticals Inc. (NASDAQ:VNDA – Get Rating) – Analysts at Jefferies Financial Group increased their FY2022 earnings per share estimates for Vanda Pharmaceuticals in a report issued on Monday, August 29th. Jefferies Financial Group analyst C. Howerton now forecasts that the biopharmaceutical company will post earnings of $0.22 per share for the year, up from their previous estimate of $0.18. The consensus estimate for Vanda Pharmaceuticals' current full-year earnings is $0.18 per share. Jefferies Financial Group also issued estimates for Vanda Pharmaceuticals' FY2023 earnings at $0.29 EPS, FY2024 earnings at $0.39 EPS, FY2025 earnings at $0.48 EPS and FY2026 earnings at $0.75 EPS.
萬達製藥公司(納斯達克代碼:VNDA-GET Rating)-傑富瑞金融集團的分析師在8月29日星期一發布的一份報告中上調了對萬達製藥2022財年每股收益的預期。傑富瑞金融集團分析師C.Howerton現在預測,這家生物製藥公司今年的每股收益將為0.22美元,高於此前預測的0.18美元。對萬達製藥目前全年收益的普遍估計是每股0.18美元。傑富瑞金融集團還發布了對萬達製藥2023財年每股收益0.29美元、2024財年每股收益0.39美元、2025財年每股收益0.48美元和2026財年每股收益0.75美元的預期。
Separately, StockNews.com raised Vanda Pharmaceuticals from a "hold" rating to a "buy" rating in a report on Friday, June 3rd.
另外,StockNews.com在6月3日週五的一份報告中將萬達製藥的評級從持有上調至買入。
Vanda Pharmaceuticals Stock Performance
中達醫藥的股票表現
Insider Transactions at Vanda Pharmaceuticals
萬達製藥的內幕交易
In other news, CMO Joakim Wijkstrom sold 3,605 shares of the business's stock in a transaction on Monday, August 22nd. The stock was sold at an average price of $10.27, for a total value of $37,023.35. Following the completion of the transaction, the chief marketing officer now directly owns 96,673 shares of the company's stock, valued at $992,831.71. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. In related news, CMO Joakim Wijkstrom sold 3,605 shares of the company's stock in a transaction on Monday, August 22nd. The stock was sold at an average price of $10.27, for a total value of $37,023.35. Following the completion of the transaction, the chief marketing officer now directly owns 96,673 shares in the company, valued at $992,831.71. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Stephen Ray Mitchell sold 2,700 shares of the company's stock in a transaction on Monday, June 13th. The shares were sold at an average price of $9.48, for a total value of $25,596.00. Following the completion of the transaction, the director now owns 6,515 shares of the company's stock, valued at $61,762.20. The disclosure for this sale can be found here. Insiders sold a total of 8,544 shares of company stock valued at $87,181 over the last three months. 7.00% of the stock is currently owned by insiders.
在其他新聞方面,CMO Joakim Wijkstrom在8月22日星期一的一次交易中出售了3605股該公司的股票。這隻股票的平均售價為10.27美元,總價值為37,023.35美元。交易完成後,首席營銷官現在直接持有該公司96,673股股票,價值992,831.71美元。這筆交易是在提交給美國證券交易委員會的一份法律文件中披露的,可以通過這個超級鏈接訪問。在相關新聞中,CMO Joakim Wijkstrom在8月22日星期一的一次交易中出售了3605股該公司的股票。這隻股票的平均售價為10.27美元,總價值為37,023.35美元。交易完成後,首席營銷官現在直接持有該公司96,673股股票,價值992,831.71美元。這筆交易是在提交給美國證券交易委員會的一份法律文件中披露的,該文件可通過美國證券交易委員會網站訪問。此外,董事的斯蒂芬·雷·米切爾在6月13日(星期一)的一次交易中出售了2,700股該公司股票。這些股票的平均價格為9.48美元,總價值為25,596.00美元。交易完成後,董事現在擁有6,515股該公司股票,價值61,762.20美元。此次拍賣的披露信息可在此處找到。在過去的三個月裏,內部人士總共出售了8,544股公司股票,價值87,181美元。該公司7.00%的股份目前由內部人士持有。
Hedge Funds Weigh In On Vanda Pharmaceuticals
對衝基金買入萬達製藥
Institutional investors have recently added to or reduced their stakes in the business. Royce & Associates LP increased its stake in Vanda Pharmaceuticals by 99.2% in the first quarter. Royce & Associates LP now owns 239,627 shares of the biopharmaceutical company's stock valued at $2,710,000 after purchasing an additional 119,329 shares during the last quarter. Citigroup Inc. grew its position in Vanda Pharmaceuticals by 62.7% during the fourth quarter. Citigroup Inc. now owns 151,874 shares of the biopharmaceutical company's stock valued at $2,383,000 after acquiring an additional 58,518 shares during the period. Campbell & CO Investment Adviser LLC purchased a new stake in Vanda Pharmaceuticals during the first quarter valued at about $119,000. Comerica Bank grew its position in Vanda Pharmaceuticals by 2.5% during the first quarter. Comerica Bank now owns 47,706 shares of the biopharmaceutical company's stock valued at $537,000 after acquiring an additional 1,180 shares during the period. Finally, ProShare Advisors LLC grew its position in Vanda Pharmaceuticals by 6.0% during the fourth quarter. ProShare Advisors LLC now owns 21,558 shares of the biopharmaceutical company's stock valued at $337,000 after acquiring an additional 1,214 shares during the period. 99.42% of the stock is currently owned by institutional investors and hedge funds.
機構投資者最近增持或減持了該公司的股份。Royce&Associates LP在第一季度增持了99.2%的萬達製藥股份。Royce&Associates LP現在擁有239,627股這家生物製藥公司的股票,價值2,710,000美元,在上個季度購買了119,329股。花旗集團(Citigroup Inc.)在第四季度增持了62.7%的萬達製藥股份。花旗集團(Citigroup Inc.)目前持有這家生物製藥公司151,874股股票,價值2,383,000美元,在此期間又購買了58,518股。Campbell&CO Investment Adviser LLC在第一季度購買了Vanda PharmPharmticals的新股份,價值約11.9萬美元。Comerica銀行在第一季度增持了2.5%的Vanda PharmPharmticals頭寸。Comerica銀行現在擁有這家生物製藥公司47,706股股票,價值537,000美元,在此期間又購買了1,180股。最後,ProShare Advisors LLC在第四季度將其在萬達製藥的頭寸增加了6.0%。ProShare Advisors LLC現在擁有這家生物製藥公司21,558股股票,價值337,000美元,在此期間又購買了1,214股。該公司99.42%的股票目前由機構投資者和對衝基金持有。
Vanda Pharmaceuticals Company Profile
萬達製藥公司簡介
(Get Rating)
(獲取評級)
Vanda Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs. The company's marketed products include HETLIOZ for the treatment of non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia.
萬達製藥公司是一家生物製藥公司,專注於療法的開發和商業化,以滿足高度未得到滿足的醫療需求。該公司的營銷產品包括用於治療非24小時睡眠-覺醒障礙的Hetlioz;以及用於治療精神分裂症的Fanapt口服藥片。
Further Reading
進一步閲讀
- Get a free copy of the StockNews.com research report on Vanda Pharmaceuticals (VNDA)
- Could Nike Stock be Oversold, but Still Overvalued?
- Is Alcoa A Buy After Strong Q2 Results And More Share Buybacks?
- Will Royal Caribbean's Broadband Partnership Drive Revenue?
- Chip Gear Maker Entegris Has Potential, But Is It Buyable Now?
- DocuSign Has Important Issues to Address When it Reports Earnings
- 免費獲取StockNews.com關於萬達製藥的研究報告(VNDA)
- 耐克股票會被超賣,但仍被高估嗎?
- 美國鋁業是在第二季度業績強勁和更多股票回購之後買入的嗎?
- 皇家加勒比的寬帶合作能否推動收入增長?
- 芯片設備製造商Entigis很有潛力,但它現在可以買下嗎?
- DocuSign在報告收益時有重要的問題需要解決
Receive News & Ratings for Vanda Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vanda Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
獲得《Vanda PharmPharmticals Daily》新聞和評級-在下面輸入您的電子郵件地址,通過MarketBeat.com的免費每日電子郵件時事通訊接收對Vanda PharmPharmticals和相關公司的最新新聞和分析師評級的每日簡要摘要。